ReviewCureus2026
Exosomal MicroRNAs as Emerging Liquid Biopsy Biomarkers in Glioma: Diagnostic, Prognostic, and Therapeutic Implications for Neuro-Oncology.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma remains the most aggressive malignant brain tumor, with limited survival despite advances in surgery, radiotherapy, and chemotherapy. Current diagnostic modalities are insufficient for early detection and precise monitoring of disease progression, prompting interest in liquid biopsy-based biomarkers. Exosomal microRNAs (miRNAs) have been highlighted as significant biomarkers due to their stability and involvement in tumor progression. This narrative review evaluates current evidence regarding the diagnostic, prognostic, and therapeutic significance of exosomal and extracellular vesicle-associated miRNAs in brain tumors, particularly gliomas. Data were collected from PubMed and Google Scholar, and eight original articles published between 2016 and 2026 were included after careful screening. The findings demonstrated dysregulated expression of exosomal miRNAs, including miR-29b, miR-210, miR-301a, miR-454-3p, and miR-2276-5p, which were significantly associated with tumor grade, recurrence, survival, and treatment response. The majority of studies reported strong diagnostic performance, with receiver operating characteristic/area under the curve values ranging from 0.80 to 0.93, while mechanistic analyses implicated these miRNAs in oncogenic pathways, including PTEN/AKT signaling, hypoxia-mediated progression, autophagy regulation, and angiogenesis. Overall, exosomal miRNAs demonstrate considerable potential as noninvasive biomarkers for prognostication and therapeutic targeting, while their dynamic preoperative alterations further suggest utility in disease monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.